Novoxel’s Tixel® device family represents a significant innovation in both ocular surface disease management and non-invasive aesthetic treatments. At the center of this breakthrough is Tixel i®, designed specifically to address Meibomian Gland Dysfunction (MGD)—one of the leading causes of dry eye disease. Using proprietary Thermo-Mechanical Action (TMA®) technology, Tixel i delivers targeted thermal energy to the eyelids without the use of drugs, needles, or lasers. Its unique ability to treat both upper and lower eyelids in a quick, two-minute session offers a practical and highly tolerable solution for patients, setting a new standard for non-pharmacologic dry eye therapies.
This technology is not only clinically effective but also strategically relevant for modern eyecare practices. Backed by recent clinical trials demonstrating its safety and efficacy, Tixel i provides physicians with a first-line treatment option that enhances patient care while reducing reliance on long-term pharmacologic regimens. In addition, the broader Tixel product family—FDA-cleared for use across all skin types and age groups—enables practices to expand into aesthetic dermatology. Treatments require no downtime, no numbing, and generate no bleeding or radiation exposure, making them ideal for integration into high-volume ophthalmic or optometric clinics.
The partnership between Novoxel and GPOphtho brings this advanced technology directly into the hands of more U.S. eyecare providers. Through this agreement, GPOphtho members gain access to preferred pricing and turnkey support for Tixel adoption. “Eyecare physicians are uniquely positioned to incorporate aesthetic procedures into their practices,” says Dr. Cynthia Matossian, CEO of GPOphtho, highlighting the synergy between clinical expertise and cosmetic care. Together, Novoxel and GPOphtho are empowering practices to deliver superior outcomes, expand service offerings, and tap into new revenue streams—demonstrating how strategic collaboration can reshape the future of eye and skin care.
MedTech Spectrum's Summary
